ANT3310 is a novel, potent and specific inhibitor of bacterial Serine Beta-Lactamases (SBLs) that displays excellent inhibitory activity against both KPC and OXA carbapenemases. It will be administered intravenously in conjunction with meropenem, for treating hospital-acquired infections caused by Gram negative pathogens, including those that are carbapenem-resistant, notably Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Acinetobacter baumannii (CRAB), which are WHO Priority Pathogens. CRAB is spreading worldwide, accounting for more than 70% of A. baumannii in many countries, and it is one of the most common causes of hospital-acquired respiratory infections. ANT3310 has received QIDP status from the FDA for complicated Urinary Tract Infection (cUTI), complicated Intra-Abdominal Infection (cIAI) and Nosocomial Pneumonia (NP). Preclinical development is in progress.